Perrigo Reports Substantial Q1 Loss of $398.6M Driven by $330.8M Goodwill Impairment Amidst Sales Decline and Increased Cash Burn

summarizeSummary

Perrigo Company plc reported a significant net loss of $398.6 million for Q1 2026, primarily due to a $330.8 million goodwill impairment, alongside decreased net sales and increased operating cash burn.

check_boxKey Events

• Substantial Net Loss Reported

  Perrigo reported a net loss of $398.6 million, or $(2.87) per diluted share, for Q1 2026, a significant increase from a $6.4 million net loss in Q1 2025. This confirms the Q1 loss previously reported in a news article and 8-K on May 6, 2026, providing full financial details.

• Major Goodwill Impairment Charge

  The Q1 loss was primarily driven by $330.8 million in goodwill impairment charges, impacting the Women's Health ($77.4M), Infant Formula ($66.3M, fully impaired), and Oral Care ($187.2M, fully impaired) reporting units.

• Decreased Net Sales and Increased Operating Cash Burn

  Total net sales declined by 7.2% to $969.2 million, primarily due to lower consumption in Self Care products. Net cash used in operating activities increased to $113.6 million in Q1 2026 from $64.5 million in Q1 2025.

• Credit Rating Downgrades and Outlook Adjustments

  S&P downgraded Perrigo's issuer credit rating to B+ from BB- on March 16, 2026. Fitch and Moody's also adjusted their outlooks to negative on March 31, 2026, and March 16, 2026, respectively, leading to an increased interest rate on 2030 notes.

auto_awesomeAnalysis

Perrigo Company plc's Q1 2026 results reveal a significant deterioration in financial performance, with a net loss of $398.6 million, primarily attributable to a substantial $330.8 million goodwill impairment charge. This impairment, affecting the Women's Health, Infant Formula, and Oral Care reporting units, signals a re-evaluation of asset values and underlying business challenges. The company also experienced a 7.2% decline in net sales and a notable increase in cash used for operating activities, indicating ongoing operational pressures. While the recent completion of the Dermacosmetics business sale for €305.6 million upfront cash and the extension of the revolving credit facility provide some liquidity and financial flexibility, these positive developments are overshadowed by the magnitude of the loss, increased restructuring charges, and recent credit rating downgrades. Investors should be concerned about the persistent legal and tax contingencies, which continue to pose potential financial risks, and the ongoing strategic review of the Infant Formula business.